Inhibitory IgG Receptor-Expressing Cells: The Must-Have Accessory for Anti-CD40 Immunomodulatory mAb Efficacy.
In this issue of Cancer Cell, Dahan and colleagues demonstrate that modified Fc regions of agonistic anti-human CD40 mAbs can drastically increase their efficiency in a mouse pre-clinical model expressing human CD40 and IgG receptors. This study also highlights the fine balance between increased treatment efficacy and secondary side effects.
Unit of Antibodies in Therapy and Pathology, Department of Immunology, Institut Pasteur, Paris 75015, France; INSERM, U1222, Paris 75015, France. Electronic address: bruhns@pasteur.fr.
Pierre
P
Bruhns
Cordeliers Research Center-INSERM UMR-S 1138, "Cancer, Immune Control and Escape" Laboratory, Paris 75006, France; Paris Descartes-Paris 5 University, UMR-S 1138, Paris 75006, France; Pierre et Marie Curie-Paris 6 University, UMR-S 1138, Paris 75006, France.
Jean-Luc
JL
Teillaud
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D019013:CD40 Antigens; D006801:Humans; D017452:Receptors, IgG
D000911:Antibodies, Monoclonal; D019013:CD40 Antigens; D017452:Receptors, IgG